Press release, April 25, 2013

Allenex AB (STO:ALNX):

  • Net sales for the quarter amounted to SEK 26.8 million (30.0). Sales were impacted by a negative currency effect of SEK 1.0 million compared to the same period last year.
  • Operating income (EBIT) for the quarter was SEK 2.0 million (3.0), with currency effects having a negative impact of SEK 1.0 million compared to the same period last year.
  • Operating margin for the quarter was 7 percent (10).
  • Loss after tax for the quarter was SEK 0.1 million (-0.4).
  • Earnings per share for the quarter, basic and diluted were SEK 0.00 (0.00).

Significant events in the first quarter

  • Allenex subsidiary AbSorber received an EU grand of EUR 215,000 over a three-year period.
  • Allenex received a breakthrough order in the U.S. for SBT Resolver? from a leading HLA typing laboratory. The yearly sales value is estimated at more than SEK 2 million.

Significant events after the period end

  • Refinancing of all Allenex loans

Allenex president and CEO Anders Karlsson's commentary on the first quarter 2013:

"Allenex continues to the launch of SBT Resolver? for sequence based typing from our Australian partner Conexio Genomics, which is a key part of the company's long-term growth strategy. Our geographic expansion of typing products from Olerup SSP to new markets also continues, with product registration processes now at final stages in key markets where our products are not yet available. The first quarter 2013 shows lower sales that last year. At the same time it can be noted that the strong Swedish krona has affected sales negatively compared to last year, while the opening quarter in 2012 was a very strong quarter. After the end of the reporting period, we also secured the refinancing of company loans".

Allenex AB discloses the information provided herein pursuant to the Securities Markets Act and /or the Financial Instruments Trading Act. The information was submitted for publication on April 25, 2013, at 08.45 CET. Allenex is a life science-company that develops, manufacture, market and sell products for safer transplants of organs and bone marrow on the global market. Allenex is listed on NASDAQ OMX Stockholm Small Cap (ticker: ALNX). 54 persons are employed in the Allenex group.

This information was brought to you by Cision http://news.cision.com

Allenex AB
Anders Karlsson
CEO
and ph.: +4670-918 00 10
e-mail: anders.karlsson@allenex.se
or
Yvonne Axelsson
CFO Allenex AB
and ph.: +468-50893972
e-mail: yvonne.axelsson@allenex.se